Amyotrophic Lateral Sclerosis References

Last updated: 25 March 2025
  1. Jackson M, Lladó J, Rothstein JD. Therapeutic developments in the treatment of amyotrophic lateral sclerosis. Expert Opin Investig Drugs. 2002 Oct;11(10):1343-1364. PMID: 12387699
  2. Andersen PM, Borasio GD, Dengler R, et al. EFNS Task Force on Management of Amyotrophic Lateral Sclerosis: guidelines for diagnosing and clinical care of patients and relatives. Eur J Neurol. 2005 Dec;12(12):921-938. PMID: 16324086
  3. Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009 Oct;73(15):1227-1233. PMID: 19822873
  4. Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet. 2011 Mar;377(9769):942-955. PMID: 21296405
  5. Kühnlein P, Gdynia HJ, Sperfeld AD, et al. Diagnosis and treatment of bulbar symptoms in amyotrophic lateral sclerosis. Nat Clin Pract Neurol. 2008 Jul;4(7):366-374. PMID: 18560390
  6. Miller RG, Mitchell JD, Lyon M, et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2002(2):CD001447. PMID: 12076411
  7. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med. 2001 May;344(22):1688-1700. PMID: 11386269
  8. Quality Standard Subcommittee of the American Academy of Neurology. Practice advisory on the treatment of amyotrophic lateral sclerosis with riluzole: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 1997 Sep;49(3):657-659. PMID: 9305318
  9. Swash M. An algorithm for ALS diagnosis and management. Neurology. 1999;53(8)(Suppl 5):S58-S62. PMID: 10560641
  10. Walling AD. Amyotrophic lateral sclerosis: Lou Gehrig’s disease. Am Fam Physician. 1999 Mar;59(6):1489-1496. PMID: 10193591
  11. Yunusova Y, Green JR, Lindstrom MJ, et al. Kinematics of disease progression in bulbar ALS. J Commun Disord. 2010 Jan;43(1):006-20. PMID: 19683250
  12. Amyotrophic lateral sclerosis and other motor neuron disorders. Harrison's Online: McGraw-Hill Companies; 2003. http://harrisonsonline.com
  13. MedWormhttp://www.medworm.com/rss/index.php/Neurology/25/http://www.medworm.com/rss/medicalfeeds/specialities/Neurology.xml
  14. Elman LB, McCluskey L. Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease. UpToDate. http://www.uptodate.com. Feb 2011. Accessed 01 Oct 2011
  15. Galvez-Jimenez N. Symptom-based management of amyotrophic lateral sclerosis. UpToDate. http://www.uptodate.com. Feb 2011. Accessed 01 Oct 2011.
  16. Choudry RB, Galvez-Jimenez N, Cudkowicz ME. Pharmacologic treatment of amyotrophic lateral sclerosis. UpToDate. http://www.uptodate.com. Jun 2011. Accessed 01 Oct 2011
  17. Brooks BR, Miller RG, Swash M; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. A consensus conference at Airlie House, Warrenton. http://www.wfnals.org/guidelines/1998elescorial/elescolrial1998.htm. Apr 1998
  18. Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol. 2011;7:639-649. doi: 10.1038/nrneurol.2011.153 . Accessed 16 Feb 2015. PMID: 21989247
  19. Rusina R, Ridzon P, Keller O, et al. Relationship between ALS and the degree of cognitive impairment, markers of neurodegenration and predictors of poor outcome: a prospective study. Eur J Neurol. 2010 Jan;17(1):23-30. doi: 10.1111/j.1468-1331.2009.02717.x. PMID: 19572947
  20. Salvioni CC, Stanich P, Almeida CS, et al. Nutritional care in motor neurone disease/amyotrophic lateral sclerosis. Arq Neuropsiquiatr. 2014 Feb;72(2):157-163. doi: 10.1590/0004-282X20130185. PMID: 24604371
  21. Choudry RB, Galvez-Jimenez N, Cudkowicz ME. Disease modifying treatment of amyotrophic lateral sclerosis. UpToDate. http://www.uptodate.com. Jun 2017.
  22. Aktekin MR, Uysal H. Epidemiology of amyotrophic lateral sclerosis. Turk J Neurol. 2020;26(3):187-196. doi:10.4274/tnd.2020.45549. Accessed 22 Jul 2022.
  23. Andersen PM, Abrahams S, Borasio GD,et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force. Eur J Neurol. 2012 Mar;19(3):360-75. doi: 10.1111/j.1468-1331.2011.03501.x. Accessed 22 Jul 2022. PMID: 21914052
  24. Barceló MA, Povedano M, Vázquez-Costa JF, et al. Estimation of the prevalence and incidence of motor neuron diseases in two Spanish regions: Catalonia and Valencia. Scientific Reports. 2021;11(1). doi:10.1038/s41598-021-85395-z. Accessed 03 Aug 2022. PMID: 33737526.
  25. Benatar M, Stanislaw C, Reyes E, et al. Presymptomatic ALS genetic counseling and testing: experience and recommendations. Neurology. 2016 Jun 14;86(24):2295-302. doi: 10.1212/WNL.0000000000002773. Accessed 03 Aug 2022. PMID: 27194384.
  26. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci. 1994 Jul;124 Suppl:96-107. doi: 10.1016/0022-510x(94)90191-0. Accessed 22 Jul 2022. PMID: 7807156.
  27. Brotman RG, Moreno-Escobar MC, Joseph J, et al. Amyotrophic lateral sclerosis. National Library of Medicine. https://www.ncbi.nlm.nih.gov. 09 May 2022. Accessed 20 Jul 2022.
  28. Center to Advance Palliative Care. Palliative care what you should know. Get Palliative Care. https://getpalliativecare.org. 18 Dec 2018. Accessed 05 Aug 2022.
  29. Chiò A, Logroscino G, Hardiman O, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009 Oct-Dec;10(5-6):310-23. doi: 10.3109/17482960802566824. Accessed 02 Aug 2022. PMID: 19922118.
  30. Dorst J, Ludolph AC. Non-invasive ventilation in amyotrophic lateral sclerosis. Ther Adv Neurol Disord. 2019 Jun 21;12:1756286419857040. doi: 10.1177/1756286419857040. Accessed 04 Aug 2022. PMID: 31258624.
  31. Edgar S, Ellis M, Abdul-Aziz NA, et al. Mutation analysis of SOD1, C9orf72, TARDBP and FUS genes in ethnically-diverse Malaysian patients with amyotrophic lateral sclerosis (ALS). Neurobiol Aging. 2021 Dec;108:200-206. doi: 10.1016/j.neurobiolaging.2021.07.008. Accessed 01 Aug 2022. PMID: 34404558.
  32. Elman LB, McCluskey L. Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease. UpToDate. https://www.uptodate.com. 02 Mar 2022. Accessed 25 Jul 2022.
  33. Filippi M, Agosta F, Abrahams S, et al. EFNS guidelines on the use of neuroimaging in the management of motor neuron diseases. Eur J Neurol. 2010 Apr;17(4):526-e20. doi: 10.1111/j.1468-1331.2010.02951.x. Accessed 22 Jul 2022. PMID: 20136647.
  34. Genuis SK, Luth W, Campbell S, et al. Communication about end of life for patients living with amyotrophic lateral sclerosis: a scoping review of the empirical evidence. Front Neurol. 2021 Aug 4;12:683197. doi: 10.3389/fneur.2021.683197. Accessed 04 Aug 2022. PMID: 34421792.
  35. Goyal NA, Galvez-Jimenez N, Cudkowicz ME. Disease-modifying treatment of amyotrophic lateral sclerosis. UpToDate. https://www.uptodate.com. 01 Aug 2022. Accessed 04 Aug 2022.
  36. Harvey B, Watson LC, Subramaniam RM, et al. Movement disorders and neurodegenerative diseases. American College of Radiology. https://acsearch.acr.org. 2019. Accessed 26 Jul 2022.
  37. Hess DR. The growing role of noninvasive ventilation in patients requiring prolonged mechanical ventilation. Respir Care. 2012 Jun;57(6):900-18; discussion 918-20. doi: 10.4187/respcare.01692. Accessed 05 Aug 2022. PMID: 22663966.
  38. Hogden A, Crook A. Patient-centered decision making in amyotrophic lateral sclerosis: where are we? Neurodegener Dis Manag. 2017 Dec;7(6):377-386. doi: 10.2217/nmt-2017-0026. Accessed 05 Aug 2022. PMID: 29165027.
  39. I AM ALS. Palliative and hospice care for ALS. I AM ALS. https://iamals.org. 21 Oct 2020. Accessed 05 Aug 2022.
  40. Ingre C, Roos PM, Piehl F, et al. Risk factors for amyotrophic lateral sclerosis. Clin Epidemiol. 2015 Feb 12;7:181-93. doi: 10.2147/CLEP.S37505. Accessed 26 Jul 2022. PMID: 25709501.
  41. Javad Mousavi SA, Zamani B, Shahabi Shahmiri S, et al. Pulmonary function tests in patients with amyotrophic lateral sclerosis and the association between these tests and survival. Iran J Neurol. 2014 Jul 4;13(3):131-7. Accessed 25 Jul 2022. PMID: 25422731.
  42. Longinetti E, Fang F. Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Curr Opin Neurol. 2019 Oct;32(5):771-776. doi: 10.1097/WCO.0000000000000730. Accessed 25 Jul 2022. PMID: 31361627.
  43. López-Gómez JJ, Ballesteros-Pomar MD, Torres-Torres B, et al. Impact of percutaneous endoscopic gastrostomy (PEG) on the evolution of disease in patients with amyotrophic lateral sclerosis (ALS). Nutrients. 2021 Aug 12;13(8):2765. doi: 10.3390/nu13082765. Accessed 05 Aug 2022. PMID: 34444925.
  44. Maragakis NJ, Galvez-Jimenez N. Epidemiology and pathogenesis of amyotrophic lateral sclerosis. UpToDate. https://www.uptodate.com. 21 Mar 2022. Accessed 27 Jul 2022.
  45. Mayo Clinic. Amyotrophic lateral sclerosis (ALS). Mayo Clinic. https://www.mayoclinic.org. 22 Feb 2022. Accessed 05 Aug 2022.
  46. McCluskey L, Ladha SS. Familial amyotrophic lateral sclerosis. UpToDate. https://www.uptodate.com. 06 Apr 2022. Accessed 25 Jul 2022.
  47. MND Australia. Motor neurone disease: aspects of care for the primary health care team. MND Australia. https://www.mndaustralia.org.au. 5 Jun 2017. Accessed 03 Aug 2022.
  48. National Institute for Health and Clinical Excellence (NICE). Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure caused by motor neurone disease. NICE. https://www.nice.org.uk. 27 Sep 2017. Accessed 26 Jul 2022.
  49. National Institute for Health and Clinical Excellence (NICE). Motor neurone disease. NICE. https://www.nice.org.uk. 27 Jul 2016. Accessed 26 Jul 2022.
  50. Plowman E. Nutrition and feeding tube placement for people with ALS: best practice in clinical decision making. Dysphagia Cafe. https://dysphagiacafe.com. 23 Oct 2014. Accessed 03 Aug 2022.
  51. Shin W, Inoue T, Nakayama Y, et al. Intention formation process for the use of tracheostomy and invasive ventilation in patients with amyotrophic lateral sclerosis. Open Journal of Nursing. 2017;07(10):1101-1114. doi:10.4236/ojn.2017.710080. Accessed 04 Aug 2022.
  52. Shoesmith C, Abrahao A, Benstead T, et al. Canadian best practice recommendations for the management of amyotrophic lateral sclerosis. CMAJ. 2020 Nov 16;192(46):E1453-E1468. doi: 10.1503/cmaj.191721. Accessed 27 Jul 2022. PMID: 33199452.
  53. The Prescriber’s Digital Reference (PDR). Rilutek (riluzole). PDR. https://www.pdr.net. 2022. Accessed 03 Aug 2022.
  54. Thomas K, Schrager J, Neel R, et al. Percutaneous endoscopic gastrostomy tube placement in amyotrophic lateral sclerosis: a case series with a multidisciplinary, team-based approach. Ann Gastroenterol. 2020 Sep-Oct;33(5):480-484. doi: 10.20524/aog.2020.0517. Accessed 27 Jul 2022. PMID: 32879594.
  55. Tortelli R, Arcuti S, Copetti M, et al. Pseudobulbar affect as a negative prognostic indicator in amyotrophic lateral sclerosis. Acta Neurol Scand. 2018 Jul;138(1):55-61. doi: 10.1111/ane.12918. Accessed 29 Jul 2022. PMID: 29527672.
  56. U.S. Food and Drug Administration (FDA). FDA approves oral form of ALS Treatment. U.S. Food and Drug Administration. https://www.fda.gov. 12 May 2022. Accessed 22 Jul 2022.
  57. Wei QQ, Ou R, Lin J, et al. Prevalence and factors related to pathological laughter and crying in patients with amyotrophic lateral sclerosis. Front Neurol. 2021 Sep 28;12:655674. doi: 10.3389/fneur.2021.655674. Accessed 25 Jul 2022. PMID: 34650501.
  58. Zou ZY, Zhou ZR, Che CH, et al. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2017 Jul;88(7):540-549. doi: 10.1136/jnnp-2016-315018. Accessed 23 Jul 2022. PMID: 28057713.